Recombinant Anti-IL17 x Anti-IL23 Bispecific Antibody (CrossMab) (CROSSAB-174)

Recombinant Anti-IL17 x Anti-IL23 Bispecific Antibody (CrossMab) is designed to be expressed as four chains with knobs-into-holes mutations and domain crossover. After one or multi-steps purification, high-purity antibody can be obtained. This BsAb can bind and inactivate two ligands simultaneously. It is designed for the research of Autoimmune diseases; Cancers therapy.

Datasheet INQUIRY

Specifications

Targets

IL17 & IL23

Type

CrossMab

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Autoimmune diseases; Cancers

Targets

Target 1

IL17

Gene ID

3605

UniProt ID

Q16552

Alternative Names

IL17A; interleukin 17A; IL17; CTLA8; IL-17; IL-17A; interleukin-17A; CTLA-8; cytotoxic T-lymphocyte-associated antigen 8; cytotoxic T-lymphocyte-associated protein 8; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8)

Target 2

IL23

Gene ID

51561

UniProt ID

Q9NPF7

Alternative Names

P19; SGRF; IL-23; IL-23A; IL23P19; Interleukin-23; IL23; interleukin 23 subunit alpha

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-IL17 x Anti-IL23 Bispecific Antibody (CrossMab) (CROSSAB-174). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-IL17 x Anti-IL23 Bispecific Antibody (CrossMab) (CAT#: CROSSAB-174)

Specifications

Targets

Customer Reviews and Q&As